A complementary role of multiparameter flow cytometry and
high-throughput sequencing for minimal residual disease
detection in chronic lymphocytic leukemia: an European Research
Initiative on CLL study

J 2016

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

RAWSTRON, A.C.; C. FAZI; A. AGATHANGELIDIS; N. VILLAMOR; R. LETESTU et al.

Základní údaje

Originální název

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

Autoři

Vydání

Leukemia, London, Nature Publishing Group, 2016, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.702

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/16:00088883

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

ASSAY; QUANTIFICATION; RITUXIMAB; SURVIVAL; THERAPY; ERADICATION; EXPRESSION; GUIDELINES; DIAGNOSIS; TRIAL

Štítky

rivok

Změněno: 6. 12. 2016 15:24, Mgr. Eva Špillingová

Anotace

V originále

In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NT13493, projekt VaV

Název: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie

Citovat

RAWSTRON, A.C.; C. FAZI; A. AGATHANGELIDIS; N. VILLAMOR; R. LETESTU; J. NOMDEDEU; C. PALACIO; Olga STEHLÍKOVÁ; K-A. KREUZER; S. LIPTROT; D. O´BRIEN; R.M. DE TUTE; I. MARINOV; M. HAUWEL; M. SPACEK; J. DOBBER; A.P. KATER; P. GAMBELL; A. SOOSAPILLA; G. LOZANSKI; G. BRACHTL; K. LIN; J. BOYSEN; C. HANSON; J.L. JORGENSEN; M. STETLER-STEVENSON; C. YUAN; H.E. BROOME; L. RASSENTI; F. CRAIG; J. DELGADO; C. MORENO; F. BOSCH; A. EGLE; Michael DOUBEK; Šárka POSPÍŠILOVÁ; S. MULLIGAN; D. WESTERMAN; C.M. SANDERS; R. EMERSON; H.S. ROBINS; I. KIRSCH; T. SHANAFELT; A. PETTITT; T.J. KIPPS; W.G. WIERDA; F. CYMBALISTA; M. HALLEK; P. HILLMEN; E. MONTSERRAT a P. GHIA. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. London: Nature Publishing Group, 2016, roč. 30, č. 4, s. 929-936. ISSN 0887-6924. Dostupné z: https://doi.org/10.1038/leu.2015.313.

@article{1354166,
   author = {Rawstron, A.C. and Fazi, C. and Agathangelidis, A. and Villamor, N. and Letestu, R. and Nomdedeu, J. and Palacio, C. and Stehlíková, Olga and Kreuzer, KandA. and Liptrot, S. and O´Brien, D. and de Tute, R.M. and Marinov, I. and Hauwel, M. and Spacek, M. and Dobber, J. and Kater, A.P. and Gambell, P. and Soosapilla, A. and Lozanski, G. and Brachtl, G. and Lin, K. and Boysen, J. and Hanson, C. and Jorgensen, J.L. and StetlerandStevenson, M. and Yuan, C. and Broome, H.E. and Rassenti, L. and Craig, F. and Delgado, J. and Moreno, C. and Bosch, F. and Egle, A. and Doubek, Michael and Pospíšilová, Šárka and Mulligan, S. and Westerman, D. and Sanders, C.M. and Emerson, R. and Robins, H.S. and Kirsch, I. and Shanafelt, T. and Pettitt, A. and Kipps, T.J. and Wierda, W.G. and Cymbalista, F. and Hallek, M. and Hillmen, P. and Montserrat, E. and Ghia, P.},
   article_location = {London},
   article_number = {4},
   doi = {https://doi.org/10.1038/leu.2015.313},
   keywords = {ASSAY; QUANTIFICATION; RITUXIMAB; SURVIVAL; THERAPY; ERADICATION; EXPRESSION; GUIDELINES; DIAGNOSIS; TRIAL},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study},
   url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832072/pdf/leu2015313a.pdf},
   volume = {30},
   year = {2016}
}

TY  - JOUR
ID  - 1354166
AU  - Rawstron, A.C. - Fazi, C. - Agathangelidis, A. - Villamor, N. - Letestu, R. - Nomdedeu, J. - Palacio, C. - Stehlíková, Olga - Kreuzer, K-A. - Liptrot, S. - O´Brien, D. - de Tute, R.M. - Marinov, I. - Hauwel, M. - Spacek, M. - Dobber, J. - Kater, A.P. - Gambell, P. - Soosapilla, A. - Lozanski, G. - Brachtl, G. - Lin, K. - Boysen, J. - Hanson, C. - Jorgensen, J.L. - Stetler-Stevenson, M. - Yuan, C. - Broome, H.E. - Rassenti, L. - Craig, F. - Delgado, J. - Moreno, C. - Bosch, F. - Egle, A. - Doubek, Michael - Pospíšilová, Šárka - Mulligan, S. - Westerman, D. - Sanders, C.M. - Emerson, R. - Robins, H.S. - Kirsch, I. - Shanafelt, T. - Pettitt, A. - Kipps, T.J. - Wierda, W.G. - Cymbalista, F. - Hallek, M. - Hillmen, P. - Montserrat, E. - Ghia, P.
PY  - 2016
TI  - A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
JF  - Leukemia
VL  - 30
IS  - 4
SP  - 929-936
EP  - 929-936
PB  - Nature Publishing Group
SN  - 08876924
KW  - ASSAY
KW  - QUANTIFICATION
KW  - RITUXIMAB
KW  - SURVIVAL
KW  - THERAPY
KW  - ERADICATION
KW  - EXPRESSION
KW  - GUIDELINES
KW  - DIAGNOSIS
KW  - TRIAL
UR  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832072/pdf/leu2015313a.pdf
L2  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832072/pdf/leu2015313a.pdf
N2  - In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.
ER  -

RAWSTRON, A.C.; C. FAZI; A. AGATHANGELIDIS; N. VILLAMOR; R. LETESTU; J. NOMDEDEU; C. PALACIO; Olga STEHLÍKOVÁ; K-A. KREUZER; S. LIPTROT; D. O´BRIEN; R.M. DE TUTE; I. MARINOV; M. HAUWEL; M. SPACEK; J. DOBBER; A.P. KATER; P. GAMBELL; A. SOOSAPILLA; G. LOZANSKI; G. BRACHTL; K. LIN; J. BOYSEN; C. HANSON; J.L. JORGENSEN; M. STETLER-STEVENSON; C. YUAN; H.E. BROOME; L. RASSENTI; F. CRAIG; J. DELGADO; C. MORENO; F. BOSCH; A. EGLE; Michael DOUBEK; Šárka POSPÍŠILOVÁ; S. MULLIGAN; D. WESTERMAN; C.M. SANDERS; R. EMERSON; H.S. ROBINS; I. KIRSCH; T. SHANAFELT; A. PETTITT; T.J. KIPPS; W.G. WIERDA; F. CYMBALISTA; M. HALLEK; P. HILLMEN; E. MONTSERRAT a P. GHIA. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. \textit{Leukemia}. London: Nature Publishing Group, 2016, roč.~30, č.~4, s.~929-936. ISSN~0887-6924. Dostupné z: https://doi.org/10.1038/leu.2015.313.

Přehled o publikaci